Prognostic role of plasma mammaglobin A expression in breast carcinoma patients: a meta-analysis
Yuanyuan Hu, Peipei Liu, Di Wu, Youhong Jiang Molecular Oncology Laboratory of Cancer Research Institute, The First Affiliated Hospital of China Medical University, Shenyang, People’s Republic of China Abstract: Mammaglobin A expression in peripheral blood (PB) of breast carcinoma patien...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-05-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/prognostic-role-of-plasma-mammaglobin-a-expression-in-breast-carcinoma-peer-reviewed-article-OTT |
id |
doaj-8bd6ac87402c429291c2397c855398ea |
---|---|
record_format |
Article |
spelling |
doaj-8bd6ac87402c429291c2397c855398ea2020-11-25T00:49:08ZengDove Medical PressOncoTargets and Therapy1178-69302018-05-01Volume 113245325538593Prognostic role of plasma mammaglobin A expression in breast carcinoma patients: a meta-analysisHu YYLiu PWu DJiang YHYuanyuan Hu, Peipei Liu, Di Wu, Youhong Jiang Molecular Oncology Laboratory of Cancer Research Institute, The First Affiliated Hospital of China Medical University, Shenyang, People’s Republic of China Abstract: Mammaglobin A expression in peripheral blood (PB) of breast carcinoma patients has been evaluated by various studies, but the findings have been inconsistent. This meta-analysis aimed to clarify the prognostic value of mammaglobin A in the PB of breast carcinoma patients and define its relationships with clinicopathological features. PubMed, EMBASE, and the Cochrane Library databases were systematically searched for eligible studies through September 26, 2017. A total of 20 studies involving 2,323 patients were analyzed, and the data were independently extracted by two researchers. The combined hazard ratios (HRs) with 95% CI was used to assess the association between survival data and plasma mammaglobin A expression, and odds ratios (ORs) and 95% CIs were used to assess the associations between clinicopathological parameters and plasma mammaglobin A expression. The results indicated that plasma mammaglobin A expression was a predictor of poor prognosis for breast carcinoma patients, with an HR of 2.08 (95% CI=1.48–2.91; P<0.0001) for overall survival. Moreover, plasma mammaglobin A was significantly associated with lymph node metastasis (OR=2.00; 95% CI=1.17–3.45; P=0.01) and advanced tumor stage (OR=3.01; 95% CI=1.57–5.77; P=0.0009) in breast carcinoma patients. However, the results revealed that plasma mammaglobin A was not significantly associated with tumor size (OR=1.29; 95% CI=0.46–3.66; P=0.63), tumor differentiation (OR=0.99; 95% CI=0.63–1.57; P=0.97), menopausal status (OR=0.75; 95% CI=0.48–1.18; P=0.22), estrogen receptor status (OR=0.78; 95% CI=0.44–1.36; P=0.38), progesterone receptor status (OR=0.76; 95% CI=0.57–1.02; P=0.07), or human epidermal growth factor receptor 2 status (OR=1.12; 95% CI=0.78–1.59; P=0.54). In conclusion, the results demonstrate that positive plasma mammaglobin A expression might serve as a biomarker of poor prognosis for breast carcinoma patients. Keywords: plasma mammaglobin A, breast carcinoma, prognosis, meta-analysis https://www.dovepress.com/prognostic-role-of-plasma-mammaglobin-a-expression-in-breast-carcinoma-peer-reviewed-article-OTTPlasma mammaglobin Abreast carcinomaprognosismeta-analysis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hu YY Liu P Wu D Jiang YH |
spellingShingle |
Hu YY Liu P Wu D Jiang YH Prognostic role of plasma mammaglobin A expression in breast carcinoma patients: a meta-analysis OncoTargets and Therapy Plasma mammaglobin A breast carcinoma prognosis meta-analysis |
author_facet |
Hu YY Liu P Wu D Jiang YH |
author_sort |
Hu YY |
title |
Prognostic role of plasma mammaglobin A expression in breast carcinoma patients: a meta-analysis |
title_short |
Prognostic role of plasma mammaglobin A expression in breast carcinoma patients: a meta-analysis |
title_full |
Prognostic role of plasma mammaglobin A expression in breast carcinoma patients: a meta-analysis |
title_fullStr |
Prognostic role of plasma mammaglobin A expression in breast carcinoma patients: a meta-analysis |
title_full_unstemmed |
Prognostic role of plasma mammaglobin A expression in breast carcinoma patients: a meta-analysis |
title_sort |
prognostic role of plasma mammaglobin a expression in breast carcinoma patients: a meta-analysis |
publisher |
Dove Medical Press |
series |
OncoTargets and Therapy |
issn |
1178-6930 |
publishDate |
2018-05-01 |
description |
Yuanyuan Hu, Peipei Liu, Di Wu, Youhong Jiang Molecular Oncology Laboratory of Cancer Research Institute, The First Affiliated Hospital of China Medical University, Shenyang, People’s Republic of China Abstract: Mammaglobin A expression in peripheral blood (PB) of breast carcinoma patients has been evaluated by various studies, but the findings have been inconsistent. This meta-analysis aimed to clarify the prognostic value of mammaglobin A in the PB of breast carcinoma patients and define its relationships with clinicopathological features. PubMed, EMBASE, and the Cochrane Library databases were systematically searched for eligible studies through September 26, 2017. A total of 20 studies involving 2,323 patients were analyzed, and the data were independently extracted by two researchers. The combined hazard ratios (HRs) with 95% CI was used to assess the association between survival data and plasma mammaglobin A expression, and odds ratios (ORs) and 95% CIs were used to assess the associations between clinicopathological parameters and plasma mammaglobin A expression. The results indicated that plasma mammaglobin A expression was a predictor of poor prognosis for breast carcinoma patients, with an HR of 2.08 (95% CI=1.48–2.91; P<0.0001) for overall survival. Moreover, plasma mammaglobin A was significantly associated with lymph node metastasis (OR=2.00; 95% CI=1.17–3.45; P=0.01) and advanced tumor stage (OR=3.01; 95% CI=1.57–5.77; P=0.0009) in breast carcinoma patients. However, the results revealed that plasma mammaglobin A was not significantly associated with tumor size (OR=1.29; 95% CI=0.46–3.66; P=0.63), tumor differentiation (OR=0.99; 95% CI=0.63–1.57; P=0.97), menopausal status (OR=0.75; 95% CI=0.48–1.18; P=0.22), estrogen receptor status (OR=0.78; 95% CI=0.44–1.36; P=0.38), progesterone receptor status (OR=0.76; 95% CI=0.57–1.02; P=0.07), or human epidermal growth factor receptor 2 status (OR=1.12; 95% CI=0.78–1.59; P=0.54). In conclusion, the results demonstrate that positive plasma mammaglobin A expression might serve as a biomarker of poor prognosis for breast carcinoma patients. Keywords: plasma mammaglobin A, breast carcinoma, prognosis, meta-analysis |
topic |
Plasma mammaglobin A breast carcinoma prognosis meta-analysis |
url |
https://www.dovepress.com/prognostic-role-of-plasma-mammaglobin-a-expression-in-breast-carcinoma-peer-reviewed-article-OTT |
work_keys_str_mv |
AT huyy prognosticroleofplasmamammaglobinaexpressioninbreastcarcinomapatientsametaanalysis AT liup prognosticroleofplasmamammaglobinaexpressioninbreastcarcinomapatientsametaanalysis AT wud prognosticroleofplasmamammaglobinaexpressioninbreastcarcinomapatientsametaanalysis AT jiangyh prognosticroleofplasmamammaglobinaexpressioninbreastcarcinomapatientsametaanalysis |
_version_ |
1725252768412729344 |